Differential Activity of NO Synthase Inhibitors as Chemopreventive Agents in a Primary Rat Tracheal Epithelial Cell Transformation System  by Sharma, Sheela et al.
Differential Activity of NO Synthase Inhibitors as
Chemopreventive Agents in a Primary Rat Tracheal Epithelial Cell
Transformation System1
Sheela Sharma*, Betty P. Wilkinson*, Pu Gao* and Vernon E. Steeley
*Cellular and Molecular Toxicology Program, ManTech Environmental Technology, Inc., Research Triangle Park,
NC 27709, USA; yChemoprevention Agent Development Research Group, National Cancer Institute, NIH,
Bethesda, MD 20892, USA
Abstract
A model to study the effectiveness of potential chemo-
preventive agents that inhibit neoplastic process by
different mechanisms has been used to test the
efficacy of seven nitric oxide synthase (NOS) inhib-
itors. Five selective inducible NOS (iNOS) inhibitors:
S -methyl isothiourea (S-MITU), S -2-aminoethyl iso-
thiourea (S-2-AEITU), S -ethyl isothiourea (S-EITU),
aminoguanidine (AG), 2-amino-4-methyl pyridine (2-
AMP), and two non selective general NOS inhibitors:
L-N6- (1- iminoethyl ) lysine ( IEL) and N !-nitro-L-argi-
nine (NNLA), were tested for efficacy against a
carcinogen, benzo[a ]pyrene (B[a ]P) - induced primary
rat tracheal epithelial (RTE) cell transformation assay.
RTE cells were treated with B[a ]P alone or with five
nontoxic concentrations of an NOS inhibitor and the
resulting foci at the end of 30 days were scored for
inhibition of transformation. The results indicate that
all three isothiourea compounds inhibited B[a ]P-
induced RTE foci in a dose-dependent manner. S-
AEITU was the most effective inhibitor with an IC50
( the molar concentration that inhibits transformation
by 50%) of 9.1 M and 100% inhibition at the highest
dose tested (30 M). However, both S-EITU and S-
MITU showed a maximum percent inhibition of 81%
and 100% at 1 mM with an IC50 of 84 and 110 M,
respectively. 2-AMP did not show any dose-depend-
ent response, but was highly effective (57% inhibition)
at an intermediate dose of 30 M and an IC50 of 25 M.
Similar to thiourea compounds, AG exhibited good
dose-dependent inhibition with a maximum inhibition
of 86% at 1 mM. NNLA and IEL were negative in this
assay. Based on the IC50 values, NOS inhibitors were
rated for efficacy from high to low as follows: S-2-
AEITU<2-AMP<AG<S-MITU<S-EITU. The data from
this study identify NOS inhibitors as a novel class of
chemopreventive agents that can be developed for
lung cancer prevention.
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Introduction
A significant number of compounds that theoretically have
chemopreventive potential can be isolated from natural
substances or synthesized. A logical approach must be
developed to efficiently evaluate the chemopreventive
properties of each compound. Although the effectiveness of
any chemopreventive agent depends on its properties in the
living animal, in vivo evaluation is very expensive and time
consuming. In vitro test systems are ideal for investigating
target organ specificity. One such in vitro method that uses
primary cultures of rat tracheal epithelial (RTE) cells was
previously developed to analyze and quantitate the process
of transformation in the respiratory system [1–5]. This
protocol was adapted for studying the inhibition of chemically
induced transformation and has been expanded to test
potential chemopreventive compounds belonging to different
chemical classes and biologic activity [6-8]. An extensive
evaluation of test data from different in vitro assays
generated for 9 years to predict the efficacy in animal model
reveals that RTE assay had the highest correlation to
hamster lung model and had the highest predictive value of
76% among the assays [9].
RTE cells provide a relevant model for studying the
effectiveness of chemopreventive agents that inhibit the
neoplastic process by different mechanisms. The RTE cell
focus inhibition assay has been shown to be sensitive to
several classes of chemopreventive agents. For example,
retinoic acid (RA) has been reported to consistently inhibit in
vitro transformation of RTE cells by carcinogen exposure
[10]. Steele et al. [12] showed that RA at a nontoxic
concentration could inhibit benzo[a ]pyrene (B[a ]P)- induced
transformation of RTE cells. Using the current protocol for the
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RTE assay [6], our laboratory has analyzed responses of a
variety of agents tested within the RTE assay in relation to
their mechanisms of action and chemical classes. For
example, analysis of data from 90 compounds revealed that
antioxidants/ free radical scavengers, including different
isomers of RAs and their derivatives, are a major mecha-
nistic class of agents that are highly effective in the RTE
transformation assay [7]. In addition, comparative chemo-
preventive efficacy of different forms of tea extracts and
other polyphenols were identified using the same trans-
formation system and several mechanism-based cell culture
assays [12,13]. In the current study, the efficacy of a new
class of antioxidants, nitric oxide synthase (NOS) inhibitors,
were identified as effective agents for the first time using a
B[a ]P- induced transformation model of primary RTE cells.
Materials and Methods
Chemicals
Aminoguanidine (AG), 2-amino-4-methyl pyridine (2-
AMP), L -N6 - (1- iminoethyl ) lysine ( IEL), S -methyl iso-
thiourea (S-MITU), N! -nitro-L-arginine (NNLA) were
obtained from Sigma Chemical (St. Louis, MO). S -2-
aminoethyl isothiourea (S-2-AEITU) and S -ethyl iso-
thiourea (S-EITU) were obtained from TCI America
(Portland, OR). Test agents were dissolved in media on
dimethyl sulfoxide.
Culture Medium and Maintenance
The RTE cultures were grown and maintained in a
modified Ham’s F-12 medium as reported by Wu et al.
[14] and incubated at 378C in an atmosphere of 5% carbon
dioxide (CO2) in air. Complete growth medium consists of
Ham’s F-12 medium mixed in equal proportion with 3T3-
conditioned Dulbecco’s minimal essential medium (DMEM)
containing 2% fetal bovine serum (FBS). This mixture was
supplemented with 10 g insulin /ml, 5 g human transferrin /
ml, 0.2% bovine hypothalamus extract, 1 M hydrocortisone,
2 g fungizone/ml, 20 g gentamycin/ml, and a FBS
concentration of 1%.
Isolation and Plating of RTE Cells
RTE cells were isolated from 8- to 12-week-old, viral
antigen- and specific pathogen- free, male Fischer 344 (F-
344) rats (Charles River, Raleigh, NC). The animals were
sacrificed by CO2 asphyxiation, the tracheae were excised
surgically, the tracheal lumens were filled with Joklik’s
minimal essential medium (Life Technologies, Rockville,
MD) and 1.0% protease (Sigma Type XIV) and the tracheae
were incubated overnight at 48C. The lumens were rinsed
with DMEM plus 10% FBS to collect the primary RTE cells,
the cells were filtered through a 100-m-pore nylon mesh,
collected by centrifugation, counted with a hemocytometer,
and resuspended in complete medium. After determining
viability by trypan blue exclusion the single-cell suspensions
were plated onto dishes previously coated with a collagen
film (600 g/60-mm dish) at 2104 cells per dish.
Dose Selection Assays
To select appropriate nontoxic doses for inhibition of
transformation, an initial cytotoxicity test was conducted for
all NOS inhibitors. The dose selection assay procedures
have been published previously [8 ]. Briefly, RTE cells plated
(2104 cells per 60-mm dish) in collagen-coated dishes
(600 g/dish) for a 24-hour attachment period, were
exposed to a carcinogen, B[a ]P (10 g/ml), plus the highest
soluble concentration of NOS inhibitors in medium or solvent
up to 1 mM (1 mg/ml) plus four log dilutions of that
concentration. After another 24 hours, the B[a ]P-containing
medium was replaced with complete culture medium
containing either chemopreventive agent or appropriate
solvent. After 5–7 days, surviving colonies of >50 cells were
counted using an automatic colony counter and the relative
cytotoxicity was determined by measuring reduction in
colony- forming efficiency (CFE) in test agent–treated
compared to untreated (solvent) control.
RTE Focus Inhibition Assay
A detailed version of the assay procedures is described
elsewhere [8]. Briefly, the RTE cells were plated and treated
with B[a ]P as described before. From the initial cytotoxicity
test, a concentration of the NOS inhibitors that reduces CFE
to approximately 80% of control levels ( i.e., a 20% or lower
reduction compared to controls) was used as the highest
concentration plus four half - log dilutions for the trans-
formation inhibition assay. Culture medium containing fresh
test agent was changed twice weekly. Between days 5 and 7,
a set of replicate cultures per group were scored for CFE and
analyzed for potential toxicity of test doses. After day 15, the
cultures were exposed to reduced serum conditions to
increase the selection pressure against normal cells and to
reduce the background rates of transformation in the control
cultures. Because transformed RTE cells require less serum
and conditioned medium to grow, after 14 days the
conditioned medium was reduced to one third [9 ], making
the final concentration of serum to be 0.5%. This reduction
allows normal cells to senesce and provides easier
identification and measurement of the transformed foci. At
day 30, the cultures on dishes were fixed in methanol,
stained with Giemsa, and scored for transformed colonies.
Three types of transformed colonies (class I, II, and III ) were
identified on the dishes according to the size of the colony,
the size of the cells, the number of cells per colony, the
staining density of the colony, as well as the morphologic
characteristics of the cells [4 ]. Previous studies [11] have
shown that class III transformed colonies or foci that have
greater than 2500 cells /mm2 progress to form tumors when
injected into nude mice. A very high percentage of class II
foci (1300–2500 cells /mm2 also became tumorigenic. Class
I foci ( <1300 cells /mm2) usually do not progress to
tumorigenicity. Therefore, only class II and III foci are
considered as evidence of morphologic transformation in
this assay. The transformation frequency was calculated by
dividing the number of class II+class III foci per dish by the
surviving colony- forming units per dish. This procedure
corrects for any cytotoxicity of the chemopreventive agent.
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The percent reduction in transformation frequency induced
by the test agent was to be calculated for each group by the
formula: TF=(TFCATFCP) /TFCA100, where TFCA is
the transformation frequency of the carcinogen alone (minus
solvent control frequency) and TFCP is the transformation
frequency of the carcinogen plus chemopreventive (NOS)-
treated cells (corrected for solvent control ). The comparison
of data from control and experimental groups was analyzed,
and an agent was considered positive if two or more
concentrations inhibit carcinogen- induced foci formation by
20% or more.
Results and Discussion
Abnormal synthesis of NO by both constitutive (neuronal and
endothelial ) and inducible ( type II ) isoforms of NOS ( iNOS)
has been implicated in a variety of human diseases including
circulatory shock. NOS inhibitors that cause nonspecific
inhibition of NO formation can result in side effects by
inhibiting the constitutive forms of NOS that are essential for
the various physiological functions of NO. To circumvent this
problem, selective NOS inhibitors such as S-MITU, S-2-
AIETU, and S-EITU, which belong to thiourea class of
compounds, were developed. They are well known for their
selective NOS inhibition especially the type II ( inducible)
NOS [14-16]. Studies also indicate that in addition to
inhibition of NOS, type II NOS inhibitors have several other
potential therapeutic applications, including treatment of
sepsis, diabetes, and autoimmune diseases [15]. A number
of in vivo studies have indicated the effectiveness of NOS
inhibitors by targeting NOS including iNOS as good targets
for chemoprevention of colon cancer in animals [17,18]. An
in vitro system of primary mouse macrophage culture
stimulated with IFN- or lipopolysaccharide has also been
used to identify novel triterpenoids as selective iNOS
inhibitors [19]. In the RTE assay, all three iNOS compounds
were highly efficacious with dose-dependent inhibition
ranging from 50% to 100% (Figure 1 ). Based on the IC50
values, S-2-AEITU was more efficacious (9.1 M) than S-
MITU (110 M) or S-EITU (84 M) (Table 1). Although both
S-MITU and S-EITU have high IC50 values, they were also
nontoxic up to 1 mM. Studies show that S-MITU significantly
inhibited the nitric oxide formation in immunostimulated
culture of macrophages and vascular smooth muscle cells
with IC50 at 6 and 2 M, respectively, and was 10- to 30- fold
more potent when compared with other inhibitors. It was used
in the therapy of circulatory shock [15]. S-EITU, another
iNOS inhibitor, decreased the lipopolysaccharide- induced
plasma nitrite and nitrate concentration by 95% in rats with an
ED50 concentration of 0.4 mg/kg. It was also found to
suppress the internucleosomal DNA cleavage in pancreatic
beta cells induced by NOS [20]. Data from another in vivo
study indicated that S-EITU (0.1 mg/kg) significantly
increased the survival time and rate in phenylephrine-
induced splanchnic artery occlusion shock in rats [21].
2-AMP, belonging to another class of type II NOS
inhibitor, was as effective as the thiourea compounds with
a maximum inhibition of 57% at 30 M and an intermediate
IC50 value of 25 M (Figure 2 ). Investigations suggest that
2-AMP can inhibit the catalytic activity NOSII enzymes both
in vitro and in vivo. 2-AMP can also inhibit lipopolysacchar-
ide- induced elevation of plasma nitrate in rats after either
subcutaneous ( ID50=0.3 mg/kg) or oral administration
( ID50=20.8 mg/kg) [22]. Early studies showed that
2-AMP facilitated neuromuscular transmission by the
inhibition of cholinesterase [23].
Table 1. Efficacy Ranking of NOS Inhibitors in Primary (RTE ) Cell
Transformation Assay.
NOS
Inhibitors
Inhibitory
Concentration
(M)
Max %
Inhibition
Result IC50 (M)
S-2 -AEITU 10–30 100 + 9.1
2 -AMP 3–300 57 + 25.4
AG 10–1000 86 + 26.0
S -EITU 300–1000 81 + 84.0
S -MITU 10–1000 100 + 110
NNLA None None  None
IEL None None  None
IC50, the molar concentration that inhibits transformation by 50%.
Figure 1. Efficacy of thiourea class of iNOS inhibitors in the RTE trans-
formation assay. Primary RTE cells were treated with B[a ]P alone or with five
half - log concentrations of each thiourea compound. Transformed colonies
( type II + III foci ) were scored at the end of 30 days and the results are
expressed as percent inhibition of transformation in compound - treated versus
untreated B[a ]P control.
Figure 2. Efficacy of other iNOS inhibitors in the RTE transformation assay.
Primary RTE cells were exposed to B[ a ]P alone or with various concen-
trations of AG and 2 -AMP and the number of transformed colonies ( type II + III
foci ) after 30 days were scored. The results are expressed as percent
inhibition of transformation in iNOS - treated versus B[ a ]P control.
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Aminoguanidine (AG), an irreversible iNOS inhibitor, was
also effective in the RTE assay, with an intermediate IC50 of
26 M (Figure 2 ) similar to 2 AMP. AG and its derivatives
have been shown to have anticancer and antiviral activities.
Studies indicate that some of the derivatives are effective in
inhibiting Rous sarcoma virus transformation of chick
fibroblast in vitro, P388 leukemia in mice [24] and
proliferation of Ehrlich ascites cells grown in culture [25].
Other studies show that eight derivatives of AG were
effective against human leukemic cells in vitro, mainly by
inhibiting ribonucleotide reductase activity with IC50 ranging
from 2.95 to 121 M [26]. Recent studies indicate that AG
also can reverse inhibition of glucose- induced angiogenesis
as a part of wound healing process in simulated diabetic rat
model [27].
Other NOS inhibitors, IEL and NNLA, which are also amino
acid derivatives, were not efficacious in the RTE assay even
at 1 mM concentrations (Figure 3 ). NNLA is a nonselective
NOS inhibitor. Studies indicate that it significantly inhibited
the nitrite accumulation in murine breast cancer cell line [28].
However, as it is a nonspecific inhibitor of both constitutive
NOS and iNOS, it may not be a desirable compound to be
developed for lung cancer prevention. Further, in vivo
studies with a pulmonary metastasis model have indicated
that L-NAME, a methyl ester of NNLA, increased the number
of metastases induced by Lewis lung carcinoma and B16
melanoma cells [29]. IEL, a nontoxic ineffective compound in
the RTE transformation system ( <20% inhibition), poten-
tially inhibited the activity of iNOS in primary macrophage of
intact cells and during the infection of mice with a NO
sensitive parasite, Leishmania major [30].
NO is an important endogenous mediator in regulating
normal airway function. However, NO synthesis mainly by
the iNOS isoform is also implicated in the pathophysiology of
inflammatory airway diseases mediated by various cytokines
[31]. The role of NO in tumorigenesis is complex with
increased NOS expression implicated in tumor progression
as well as metastasis [32-38]. When NO is produced at high
concentrations mainly by iNOS alone, it has both cytotoxic
and cytostatic properties leading to DNA damage, an initial
step in carcinogenesis. However, at conditions of low
concentrations generated mostly by constitutive NOS iso-
forms, tumor growth is enhanced by NO’s antiapoptotic
effects along with its ability to induce angiogenesis [39].
Therefore, it is critical to select an NOS inhibitor that is
specific for the inducible isoform in cancer prevention or
treatment scenario. The data from this study identify a new
class of compounds, NOS inhibitors, especially the iNOS
inhibitors ( in addition to their other desirable biologic
activities described above) as effective chemopreventive
agents that can be developed as agents for lung cancer
prevention. Further preclinical studies of these inhibitors in in
vivo lung cancer models would be of great interest.
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